Detail

Keywords

Molecular Imaging; Prostate; Prostate-Specific Antigen; Prostatectomy

Selected publications

1. Grubmüller, B. et al., 2018. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 46(5), pp.1063,
2. Grubmüller, B. et al., 2018. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 24(24), pp.6300,
3. Grubmüller, B. et al., 2017. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making. European Journal of Nuclear Medicine and Molecular Imaging, 45(2), pp.235–242. Available at: http://dx.doi.org/10.1007/s00259-017-3858-2.
4. Grubmüller, B. et al., 2016. 64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. Cancer Biotherapy and Radiopharmaceuticals, 31(8), pp.277,
5. Abufaraj, M. et al., 2019. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 46(10), pp.2169,